Oral Methotrexate/6-mercaptopurine may be Superior to a Multidrug LSA: Results From the NOPHO ALL-92 Study2: Results From the NOPHO ALL-92 StudyL: Results From the NOPHO ALL-92 Study2: Results From the NOPHO ALL-92 Study Maintenance Therapy for Higher Risk Childhood Acute Lymphoblastic Leukemia: Results From the NOPHO ALL-92 Study

    loading  Checking for direct PDF access through Ovid

Abstract

The importance of maintenance therapy for higher risk childhood acute lymphoblastic leukemia (ALL) is uncertain. Between 1992 and 2001 the Nordic Society for Pediatric Haematology/Oncology compared in a nonrandomized study conventional oral methotrexate (MTX)/6-mercaptopurine (6MP) maintenance therapy with a multidrug cyclic LSA2L2 regimen. 135 children with B-lineage ALL and a white blood count ≥50×109/L and 98 children with T-lineage ALL were included. Of the 234 patients, the 135 patients who received MTX/6MP maintenance therapy had a lower relapse risk than the 98 patients who received LSA2L2 maintenance therapy, which was the case for both B-lineage (27%±5% vs. 45%±9%; P=0.02) and T-lineage ALL (8%±5% vs. 21%±5%; P=0.12). In multivariate Cox regression analysis stratified for immune phenotype, a higher white blood count (P=0.01) and administration of LSA2L2 maintenance therapy (P=0.04) were both related to an increased risk of an event (overall P value of the Cox model: 0.003), whereas neither sex, age at diagnosis, administration of central nervous system irradiation, nor presence of a day 15 bone marrow with ≥25% versus <25% lymphoblasts were of statistical significance. These results indicate that oral MTX/6MP maintenance therapy administered after the first year of remission can improve the cure rates of children with T-lineage or with higher risk B-lineage ALL.

Related Topics

    loading  Loading Related Articles